In Vivo Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models-Reference-Cited by-同舟云学术

In Vivo Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models

Published:2017-05-31 Issue:8 Volume:16 Page:1566-1575
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Cornillie Jasmien,Wozniak Agnieszka,Pokreisz Peter,Casazza Andrea,Vreys Lise,Wellens Jasmien,Vanleeuw Ulla,Gebreyohannes Yemarshet K.,Debiec-Rychter Maria,Sciot Raf,Hompes Daphne,Schöffski Patrick

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ‘Renovation of old drugs’ – can peptide drug conjugates lead the post-ADC era?;Australian Journal of Chemistry;2023-06-30

2. Enapotamab Vedotin, an AXL-Specific Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Patient-Derived Xenograft Models of Soft Tissue Sarcoma;International Journal of Molecular Sciences;2022-07-06

3. Plocabulin, a Novel Tubulin Inhibitor, Has Potent Antitumour Activity in Patient-Derived Xenograft Models of Soft Tissue Sarcoma;International Journal of Molecular Sciences;2022-07-05

4. Enhanced Antitumor Efficacy of PhAc-ALGP-Dox, an Enzyme-Activated Doxorubicin Prodrug, in a Panel of THOP1-Expressing Patient-Derived Xenografts of Soft Tissue Sarcoma;Biomedicines;2022-04-06

5. PhAc-ALGP-Dox, a Novel Anticancer Prodrug with Targeted Activation and Improved Therapeutic Index;Molecular Cancer Therapeutics;2022-02-11